These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31928727)

  • 1. Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.
    Mendre C; Mouillac B
    Adv Protein Chem Struct Biol; 2019; 118():249-272. PubMed ID: 31928727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
    Mouillac B; Mendre C
    Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
    Mouillac B; Mendre C
    Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.
    Jean-Alphonse F; Perkovska S; Frantz MC; Durroux T; Méjean C; Morin D; Loison S; Bonnet D; Hibert M; Mouillac B; Mendre C
    J Am Soc Nephrol; 2009 Oct; 20(10):2190-203. PubMed ID: 19729439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
    Los EL; Deen PM; Robben JH
    J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
    Robben JH; Deen PM
    BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
    J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V2 vasopressin receptor mutations.
    Makita N; Manaka K; Sato J; Iiri T
    Vitam Horm; 2020; 113():79-99. PubMed ID: 32138955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
    J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vasopressin V2 receptor-related pathologies: congenital nephrogenic diabetes insipidus and nephrogenic syndrome of inappropiate antidiuresis].
    Morin D
    Nephrol Ther; 2014 Dec; 10(7):538-46. PubMed ID: 25449762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic diabetes insipidus.
    Morello JP; Bichet DG
    Annu Rev Physiol; 2001; 63():607-30. PubMed ID: 11181969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.
    Schoneberg T; Yun J; Wenkert D; Wess J
    EMBO J; 1996 Mar; 15(6):1283-91. PubMed ID: 8635461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.
    Janovick JA; Spicer TP; Smith E; Bannister TD; Kenakin T; Scampavia L; Conn PM
    Mol Cell Endocrinol; 2016 Oct; 434():176-85. PubMed ID: 27389877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.
    Smith E; Janovick JA; Bannister TD; Shumate J; Scampavia L; Conn PM; Spicer TP
    J Biomol Screen; 2016 Sep; 21(8):824-31. PubMed ID: 27280550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
    Bichet DG; Turner M; Morin D
    Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
    Janovick JA; Spicer TP; Bannister TD; Smith E; Ganapathy V; Scampavia L
    Biochem J; 2018 Sep; 475(18):2941-2953. PubMed ID: 30068530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V2R mutations and nephrogenic diabetes insipidus.
    Bichet DG
    Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
    Bernier V; Lagacé M; Lonergan M; Arthus MF; Bichet DG; Bouvier M
    Mol Endocrinol; 2004 Aug; 18(8):2074-84. PubMed ID: 15166253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.